Rexulti (brexpiprazole) was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015 [1].
What is Rexulti used for?
Rexulti is approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder in adults [1].
How does Rexulti work?
Rexulti is a partial agonist of dopamine D2 and serotonin 5-HT1A receptors, and an antagonist of serotonin 5-HT2A receptors [1]. Its mechanism of action in schizophrenia and depression is not fully understood [1].
When does Rexulti's patent expire?
Patent expiry dates for drugs can be complex and may involve multiple patents covering different aspects of the drug. Information on specific patent expiries for Rexulti can be found on DrugPatentWatch.com [2].
Are there other drugs like Rexulti?
Rexulti belongs to a class of medications known as atypical antipsychotics or second-generation antipsychotics. Other drugs in this class include aripiprazole (Abilify), lurasidone (Latuda), and brexpiprazole itself, which is also sold as an authorized generic. These medications work on different neurotransmitter systems in the brain.
What are the common side effects of Rexulti?
Common side effects of Rexulti include weight gain, somnolence (sleepiness), and akathisia (a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion) [1].
Who makes Rexulti?
Rexulti was developed by Otsuka Pharmaceutical and Lundbeck [3].